FDA Brief

Warning letters Drugs

FDA warning letter to

Furley Bioextracts SDN BHD

High riskIssued Sep 13, 2021Posted Sep 21, 2021Center for Drug Evaluation and Research | CDER

FDA warns Furley Bioextracts over manufacturing failures and unapproved PainFix Relief Gel for the U.S. market.

What happened

FDA reviewed records Furley Bioextracts submitted after FDA's Nov. 5, 2020, request under section 704(a)(4) of the FD&C Act, a records request FDA can use without an inspection. FDA found that PainFix Relief Gel shipped to the U.S. was not tested for menthol identity and strength, incoming active ingredient was not identity-tested, and no stability data supported the labeled expiry. FDA also reviewed the product label and website and found claims showing PainFix Relief Gel was an unapproved new drug and misbranded.

What FDA found

  1. The company did not test each finished batch of PainFix Relief Gel for the identity and strength of menthol before release.

    21 CFR 211.165(a)
  2. The company did not test incoming active ingredient lots for identity; it relied on the supplier's certificate of analysis (a supplier's test report).

    21 CFR 211.84(d)(1)
  3. The company had no adequate stability data to support the labeled expiration date for PainFix Relief Gel.

    21 CFR 211.137(a)
  4. PainFix Relief Gel was an unapproved new drug because it was not generally recognized as safe and effective and no FDA approval was in effect.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  5. PainFix Relief Gel was misbranded because it did not meet the requirements for marketing under section 505G and had no approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)
  6. The company lacked process validation, did not qualify equipment, and its batch production records did not document each significant manufacturing step.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days, specifying corrective and preventive actions; if it cannot finish within 15 working days, it must give reasons and a completion schedule.

Who should pay attention

  • brands and distributors selling PainFix Relief Gel in the U.S.
  • U.S. importers of OTC drugs from this manufacturer
  • quality teams that rely on supplier certificates of analysis

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk